These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 36306609)

  • 1. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the risk of serious infections in patients with and without MS: A German claims data analysis.
    Knapp R; Hardtstock F; Wilke T; Maywald U; Chognot C; Craveiro L; Rouzic EM
    Mult Scler Relat Disord; 2023 Apr; 72():104583. PubMed ID: 36905817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
    Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
    Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.
    Erdogan T; Cansu C; Kocer B; Akkaya S; Kokmen H
    Acta Neurol Belg; 2024 Aug; 124(4):1385-1391. PubMed ID: 38769274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
    Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
    J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
    [No Abstract]   [Full Text] [Related]  

  • 9. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
    Ohlmeier C; Gothe H; Haas J; Osowski U; Weinhold C; Blauwitz S; Schmedt N; Galetzka W; Berkemeier F; Tackenberg B; Stangel M
    PLoS One; 2020; 15(5):e0231846. PubMed ID: 32357176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors.
    Etemadifar M; Salari M; Esnaashari A; Ghazanfaripoor F; Sayahi F; Akhavan Sigari A; Sedaghat N
    Mult Scler Relat Disord; 2022 Feb; 58():103488. PubMed ID: 34999375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany.
    Müller S; Heidler T; Fuchs A; Pfaff A; Ernst K; Ladinek G; Wilke T
    Neurol Ther; 2020 Jun; 9(1):67-83. PubMed ID: 31832974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis.
    Gernert JA; Böhm L; Starck M; Buchka S; Kümpfel T; Kleiter I; Havla J
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
    Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum amino acid profiling in differentiating clinical outcomes of multiple sclerosis.
    Rzepiński Ł; Kośliński P; Kowalewski M; Koba M; Maciejek Z
    Neurol Neurochir Pol; 2023; 57(5):414-422. PubMed ID: 37526173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.
    Tutuncu M; Tang J; Zeid NA; Kale N; Crusan DJ; Atkinson EJ; Siva A; Pittock SJ; Pirko I; Keegan BM; Lucchinetti CF; Noseworthy JH; Rodriguez M; Weinshenker BG; Kantarci OH
    Mult Scler; 2013 Feb; 19(2):188-98. PubMed ID: 22736750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of MSBase criteria to diagnose secondary progressive multiple sclerosis in large German real-world patient cohort.
    Stefan B; Eleni K; Philip VH; Arnfin B; Jelena S; Aksel S; Ntd Study Group ; Refik P
    Mult Scler Relat Disord; 2024 Oct; 90():105844. PubMed ID: 39197353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study.
    Deri N; Barboza A; Vrech C; Rey R; Burgos M; Fiol M; CalvoVildoso C; Patrucco L; Jose G; Aliberti P; Chirico D; Federico MB; Seifer G; Piedrabuena R
    Mult Scler Relat Disord; 2024 Mar; 83():105421. PubMed ID: 38244525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of antioxidant parameters of multiple sclerosis patients' serum according to the disease course.
    Nowak-Kiczmer M; Niedziela N; Zalejska-Fiolka J; Adamczyk-Sowa M
    Mult Scler Relat Disord; 2023 Sep; 77():104875. PubMed ID: 37454567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
    Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.